Kovack Advisors Inc. Makes New Investment in GeneDx Holdings Corp. $WGS

Kovack Advisors Inc. purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,510 shares of the company’s stock, valued at approximately $232,000.

A number of other large investors have also bought and sold shares of the stock. Chung Wu Investment Group LLC grew its holdings in GeneDx by 8.2% in the second quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock worth $305,000 after purchasing an additional 250 shares during the period. GAMMA Investing LLC lifted its stake in shares of GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock valued at $39,000 after buying an additional 264 shares in the last quarter. Palisades Investment Partners LLC lifted its stake in shares of GeneDx by 0.4% in the first quarter. Palisades Investment Partners LLC now owns 83,913 shares of the company’s stock valued at $7,432,000 after buying an additional 309 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after buying an additional 453 shares in the last quarter. Finally, US Bancorp DE lifted its stake in shares of GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after buying an additional 548 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on WGS shares. Piper Sandler raised their price objective on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, September 11th. BTIG Research raised their price objective on shares of GeneDx from $140.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wells Fargo & Company raised their price objective on shares of GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Canaccord Genuity Group set a $160.00 price objective on shares of GeneDx and gave the company a “buy” rating in a research note on Wednesday. Finally, Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.22.

GeneDx Stock Up 4.1%

GeneDx stock opened at $136.91 on Monday. GeneDx Holdings Corp. has a fifty-two week low of $55.17 and a fifty-two week high of $146.00. The stock has a market cap of $3.93 billion, a PE ratio of 1,521.22 and a beta of 2.00. The firm’s 50-day simple moving average is $124.27 and its 200 day simple moving average is $98.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The business had revenue of $116.74 million for the quarter, compared to analysts’ expectations of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. Research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Insider Activity at GeneDx

In other GeneDx news, Director Casdin Capital, Llc sold 500,000 shares of GeneDx stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $120.90, for a total value of $60,450,000.00. Following the sale, the director owned 3,007,164 shares of the company’s stock, valued at approximately $363,566,127.60. The trade was a 14.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Katherine Stueland sold 2,158 shares of GeneDx stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $136.54, for a total transaction of $294,653.32. Following the completion of the sale, the chief executive officer directly owned 3,436 shares in the company, valued at approximately $469,151.44. This represents a 38.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 556,375 shares of company stock worth $67,569,247. Insiders own 29.60% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.